Trillium Asset Management LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) in the 2nd quarter, HoldingsChannel reports. The fund bought 3,351 shares of the medical research company’s stock, valued at approximately $647,000.
Several other large investors have also added to or reduced their stakes in the business. Brighton Jones LLC increased its holdings in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after purchasing an additional 2,537 shares in the last quarter. Empowered Funds LLC lifted its holdings in shares of IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of IQVIA in the second quarter valued at approximately $514,000. First Trust Advisors LP boosted its position in shares of IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after buying an additional 11,845 shares during the last quarter. Finally, NewEdge Advisors LLC grew its holdings in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock worth $3,582,000 after buying an additional 1,155 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.
Wall Street Analysts Forecast Growth
IQV has been the subject of a number of analyst reports. TD Cowen increased their price target on IQVIA from $233.00 to $288.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. JPMorgan Chase & Co. increased their target price on shares of IQVIA from $225.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Finally, Mizuho upped their price objective on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $241.88.
Insider Buying and Selling at IQVIA
In other news, insider Bhavik Patel sold 1,855 shares of the firm’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the completion of the transaction, the insider directly owned 1,348 shares of the company’s stock, valued at $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total value of $1,245,800.00. Following the sale, the insider owned 20,999 shares in the company, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 12,913 shares of company stock valued at $3,098,793. 1.70% of the stock is owned by corporate insiders.
IQVIA Stock Up 1.6%
Shares of NYSE IQV opened at $260.17 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The stock has a market capitalization of $42.82 billion, a PE ratio of 32.28, a P/E/G ratio of 2.17 and a beta of 1.18. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $260.40. The business’s fifty day moving average price is $213.32 and its 200-day moving average price is $187.52.
IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. The business had revenue of $4.37 billion for the quarter, compared to analysts’ expectations of $4.30 billion. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the previous year, the business posted $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current year.
IQVIA declared that its board has approved a share repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.
IQVIA Company Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Stories
- Five stocks we like better than IQVIA
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
